Is Phathom Pharmaceuticals Stock a Good Investment?
Phathom Pharmaceuticals Investment Advice | PHAT |
- Examine Phathom Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Phathom Pharmaceuticals' leadership team and their track record. Good management can help Phathom Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Phathom Pharmaceuticals' business and its evolving consumer preferences.
- Compare Phathom Pharmaceuticals' performance and market position to its competitors. Analyze how Phathom Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Phathom Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Phathom Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Phathom Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Phathom Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Phathom Pharmaceuticals Stock
Researching Phathom Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 92.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.74. Phathom Pharmaceuticals had not issued any dividends in recent years.
To determine if Phathom Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Phathom Pharmaceuticals' research are outlined below:
| Phathom Pharmaceuticals generated a negative expected return over the last 90 days | |
| Phathom Pharmaceuticals has high historical volatility and very poor performance | |
| Phathom Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 682 K. Net Loss for the year was (201.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Phathom Pharmaceuticals currently holds about 207.39 M in cash with (137.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39. | |
| Phathom Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Phathom Pharmaceuticals Stock Price Down 6.2 percent Whats Next |
Phathom Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Phathom Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Phathom Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Phathom Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Phathom Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Phathom Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-08-06 | 2020-06-30 | -0.56 | -0.64 | -0.08 | 14 | ||
2022-05-10 | 2022-03-31 | -0.97 | -1.07 | -0.1 | 10 | ||
2020-05-12 | 2020-03-31 | -0.72 | -0.62 | 0.1 | 13 | ||
2023-11-09 | 2023-09-30 | -0.89 | -0.76 | 0.13 | 14 | ||
2023-08-10 | 2023-06-30 | -0.98 | -0.84 | 0.14 | 14 | ||
2024-11-07 | 2024-09-30 | -1.49 | -1.32 | 0.17 | 11 | ||
2024-08-08 | 2024-06-30 | -1.38 | -1.56 | -0.18 | 13 | ||
2021-05-11 | 2021-03-31 | -1.19 | -0.96 | 0.23 | 19 |
Know Phathom Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Phathom Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Phathom Pharmaceuticals backward and forwards among themselves. Phathom Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Phathom Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Checkpoint Capital Lp | 2024-09-30 | 1.5 M | Federated Hermes Inc | 2024-09-30 | 1.4 M | Fmr Inc | 2024-09-30 | 1.3 M | Portolan Capital Management, Llc | 2024-06-30 | 1.1 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.1 M | Catalys Pacific Llc | 2024-09-30 | 1.1 M | 683 Capital Management Llc | 2024-09-30 | 1 M | Saturn V Capital Management Llc | 2024-09-30 | 874.6 K | Propel Bio Management Llc | 2024-06-30 | 869.9 K | Medicxi Ventures Management (jersey) Ltd | 2024-09-30 | 7.5 M | Jennison Associates Llc | 2024-09-30 | 5.9 M |
Phathom Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 613.35 M.Market Cap |
|
Phathom Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.49) | (0.51) | |
| Return On Equity | 2.77 | 2.91 |
Determining Phathom Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Phathom Pharmaceuticals is a good buy. For example, gross profit margin measures Phathom Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Phathom Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Phathom Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Phathom Pharmaceuticals. Check Phathom Pharmaceuticals' Beneish M Score to see the likelihood of Phathom Pharmaceuticals' management manipulating its earnings.
Evaluate Phathom Pharmaceuticals' management efficiency
Phathom Pharmaceuticals has return on total asset (ROA) of (0.5767) % which means that it has lost $0.5767 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.89) %, meaning that it created substantial loss on money invested by shareholders. Phathom Pharmaceuticals' management efficiency ratios could be used to measure how well Phathom Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 2.91 in 2024, whereas Return On Tangible Assets are likely to drop (0.51) in 2024. At this time, Phathom Pharmaceuticals' Non Current Liabilities Total is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 325 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 26.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.42) | (1.35) | |
| Tangible Book Value Per Share | (1.42) | (1.35) | |
| Enterprise Value Over EBITDA | (1.42) | (1.49) | |
| Price Book Value Ratio | (6.44) | (6.76) | |
| Enterprise Value Multiple | (1.42) | (1.49) | |
| Price Fair Value | (6.44) | (6.76) | |
| Enterprise Value | 225.9 M | 214.6 M |
Evaluating the management effectiveness of Phathom Pharmaceuticals allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Phathom Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 0.718 |
Basic technical analysis of Phathom Stock
As of the 1st of December, Phathom Pharmaceuticals holds the Risk Adjusted Performance of (0.09), variance of 33.81, and Coefficient Of Variation of (802.15). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phathom Pharmaceuticals, as well as the relationship between them.Phathom Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Phathom Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Phathom Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Phathom Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Henderson Molly over two months ago Disposition of 2159 shares by Henderson Molly of Phathom Pharmaceuticals at 9.6 subject to Rule 16b-3 | ||
Henderson Molly over two months ago Acquisition by Henderson Molly of 7500 shares of Phathom Pharmaceuticals subject to Rule 16b-3 | ||
Terrie Curran over three months ago Disposition of 33848 shares by Terrie Curran of Phathom Pharmaceuticals at 11.72 subject to Rule 16b-3 | ||
Karbe Frank over six months ago Acquisition by Karbe Frank of 25000 shares of Phathom Pharmaceuticals at 10.1645 subject to Rule 16b-3 | ||
David Socks over six months ago Disposition of 17500 shares by David Socks of Phathom Pharmaceuticals at 10.3 subject to Rule 16b-3 | ||
Henderson Molly over six months ago Disposition of 3435 shares by Henderson Molly of Phathom Pharmaceuticals at 11.1 subject to Rule 16b-3 | ||
David Socks over a year ago Acquisition by David Socks of 9000 shares of Phathom Pharmaceuticals subject to Rule 16b-3 |
Phathom Pharmaceuticals' Outstanding Corporate Bonds
Phathom Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Phathom Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Phathom bonds can be classified according to their maturity, which is the date when Phathom Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US717265AM45 Corp BondUS717265AM45 | View | |
| FCX 7125 01 NOV 27 Corp BondUS717265AJ16 | View | |
| US717265AL61 Corp BondUS717265AL61 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View |
Understand Phathom Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Phathom Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (2.73) | |||
| Mean Deviation | 3.76 | |||
| Coefficient Of Variation | (802.15) | |||
| Standard Deviation | 5.81 | |||
| Variance | 33.81 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (1.71) | |||
| Treynor Ratio | (2.74) | |||
| Maximum Drawdown | 35.62 | |||
| Value At Risk | (6.83) | |||
| Potential Upside | 6.89 | |||
| Skewness | (2.10) | |||
| Kurtosis | 8.12 |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (2.73) | |||
| Mean Deviation | 3.76 | |||
| Coefficient Of Variation | (802.15) | |||
| Standard Deviation | 5.81 | |||
| Variance | 33.81 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (1.71) | |||
| Treynor Ratio | (2.74) | |||
| Maximum Drawdown | 35.62 | |||
| Value At Risk | (6.83) | |||
| Potential Upside | 6.89 | |||
| Skewness | (2.10) | |||
| Kurtosis | 8.12 |
Consider Phathom Pharmaceuticals' intraday indicators
Phathom Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Phathom Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Phathom Pharmaceuticals Corporate Filings
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of November 2024 Other Reports | ViewVerify | |
F3 | 22nd of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Phathom Stock media impact
Far too much social signal, news, headlines, and media speculation about Phathom Pharmaceuticals that are available to investors today. That information is available publicly through Phathom media outlets and privately through word of mouth or via Phathom internal channels. However, regardless of the origin, that massive amount of Phathom data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Phathom Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Phathom Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Phathom Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Phathom Pharmaceuticals alpha.
Phathom Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Phathom Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Phathom Pharmaceuticals Corporate Management
| Anthony Guzzo | Chief Officer | Profile | |
| Joseph JD | Chief Officer | Profile | |
| Tom Harris | Chief Officer | Profile | |
| Martin Gilligan | Chief Officer | Profile | |
| JD Esq | General Secretary | Profile | |
| David Socks | CoFounder Director | Profile |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.